jueves, 3 de febrero de 2022

FDA Restricts Use of Bam/Ete and REGEN-COV; ASPR Pauses Allocation

https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/important-update-24Jan2022.aspx

No hay comentarios: